SEER Seer Inc
- 2.110
- -0.010-0.47%
- 2.110
- 0.0000.00%
Seer Inc News
Seer Inc (SEER) Q1 2024 Earnings: Revenue Declines but Losses Narrow, Meeting Some Analyst ...
Earnings Call Summary | Seer Inc(SEER.US) Q1 2024 Earnings Conference
The following is a summary of the Seer, Inc. (SEER) Q1 2024 Earnings Call Transcript:Financial Performance:Seer, Inc. reported Q1 2024 revenues of $3.1 million, a decrease due to slower adoption and u
Seer Inc (SEER) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges With ...
Seer Sees FY24 Revenue $16M-$18M Vs $18.9M Estimate
Seer Sees FY24 Revenue $16M-$18M Vs $18.9M Estimate
Seer Q1 2024 GAAP EPS $(0.32) Beats $(0.34) Estimate, Sales $3.066M Miss $3.800M Estimate
Seer (NASDAQ:SEER) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 15.79 percent increase over losses of $(0.38) per shar
Earnings Flash (SEER) SEER Posts Q1 Revenue $3.1M, Vs. Street Est of $3.8M
04:49 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (SEER) SEER Posts Q1 Revenue $3.1M, vs. Street Est of $3.8M
Seer Inc | 10-Q: Quarterly report
Press Release: Seer Reports First Quarter 2024 Financial Results
Seer Reports First Quarter 2024 Financial Results Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications REDWOOD CITY, Calif., May 0
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
New Seer Technology Access Center to open in Bonn, GermanyProvides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph Product Suite and mass spectrometr
Seer Reports First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publicationsREDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEE
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it
Seer, Inc. (NASDAQ:SEER) Is a Favorite Amongst Institutional Investors Who Own 51%
Candel Therapeutics Receives FDA Orphan Drug Designation for Its Pancreatic Cancer Treatment
Seer Inc(SEER.US) Officer Sells US$107.42K in Common Stocks
$Seer Inc(SEER.US)$ Officer Farokhzad Omid sold 52,857 shares of Common Stocks on Mar 7, 2024 at an average price of $2.0323 for a total value of $107.42K.Source: Announcement What is statement of cha
Seer Price Target Announced at $7.00/Share by Morgan Stanley
Seer Price Target Announced at $7.00/Share by Morgan Stanley
Morgan Stanley Reinstates Equal-Weight on Seer, Announces $7 Price Target
Morgan Stanley analyst Yuko Oku reinstates Seer with a Equal-Weight and announces $7 price target.
Seer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 257.14% Morgan Stanley → $7 Reinstates → Equal-Weight 02/21/2023 410.2% Morgan Stanley $11 → $1
Seer, Inc. (NASDAQ:SEER) Just Reported, And Analysts Assigned A US$7.00 Price Target
Earnings Call Summary | Seer Inc(SEER.US) Q4 2023 Earnings Conference
The following is a summary of the Seer, Inc. (SEER) Q4 2023 Earnings Call Transcript:Financial Performance:Seer reported a Q4 2023 revenue of $4.4 million, a 4% decrease from Q4 2022, primarily due to
Seer Sees FY24 Revenue $18M-$20M Vs $19.801M Est.
Seer Sees FY24 Revenue $18M-$20M Vs $19.801M Est.
Analysis
Price Target
No Data
